GSK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
- Primary completion Nov 19, 2026Sponsor estimatePhase 1NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, BacterialActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 2NCT06567782A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III...GlaxoSmithKline · Neoplasms, ColonRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimatePhase 3NCT07596199A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese...GlaxoSmithKline · Diphtheria-Tetanus-acellular Pertussis VaccinesActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2026Sponsor estimatePhase 3NCT03981796A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or...Tesaro, Inc. · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsMemorial Sloan Kettering Cancer Center · Rectal AdenocarcinomaRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07017803Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa RegionCentre de Recherche Médicale de Lambaréné · Multidrug-resistant Tuberculosis (MDR-TB)RecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT05349227Comprehensive Outcomes for After Cancer HealthPack Health · Ovarian CancerRecruitingGILDCollaboratorGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05718323Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCETOP IBCSG Partners Foundation · SCLC,Extensive StageRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06258018Niraparib and Temozolomide in Patients GlioblastomaArmando Santoro, MD · Glioma, MalignantNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06389058Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare SystemSan Diego State University · Severe AsthmaActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT06489964Addressing Unfunded Vaccines Through a Co-payment Mechanism in PharmaciesCanadian Immunization Research Network · Preventable Disease, VaccineRecruitingAZNCollaboratorGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 4NCT06967753Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral...UBATEC · HIVRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT04992013Niraparib in Tumors Metastatic to the CNSMassachusetts General Hospital · Metastatic CancerActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06238635Dostarlimab and Cobolimab in Advanced Cervical CancerMeghan Shea · Cervical CancerActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 1NCT07464314A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in AdultsGlaxoSmithKline · Influenza, Human+COVID-19RecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 2NCT03441113Extended Access of Momelotinib in Adults With MyelofibrosisGlaxoSmithKline · Primary MyelofibrosisActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 2NCT06317311A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent...GlaxoSmithKline · CarcinomaActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 3NCT06806137A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3...GlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 1NCT06154837A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseGlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 25, 2026Sponsor estimatePhase 3NCT06740630A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2026Sponsor estimatePhase 2NCT04641247A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyGlaxoSmithKline · Ovarian NeoplasmsRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2026Sponsor estimatePhase 3NCT07645248A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and...GlaxoSmithKline · AsthmaRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT03945721A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsMassachusetts General Hospital · Triple Negative Breast CancerActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 12 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.